EPIQ

If you acquired shares of Osiris Therapeutics, Inc. ("Osiris" or the "Company") between May 12, 2014 and November 16, 2015, you could receive a payment from a Class Action Settlement... The Settlement resolves the Litigation concerning whether Osiris Therapeutics, Inc., Lode Debrabandere, Gregory Law and Philip R. Jacoby, Jr. (collectively "Defendants") violated federal securities laws by making materially false statements, and deceptively omitting material facts, as a consequence of Defendants' alleged efforts to artificially inflate the Company's reported revenues and mislead Osiris's shareholders and the public as to Osiris's revenue and revenue growth. On November 2, 2017, Mr. Jacoby entered a plea of guilty (the "Jacoby Plea") in the criminal action styled USA v. Jacoby, No. 1:17-cv-00676 (S.D.N.Y.). With the exception of the Jacoby Plea, Defendants have denied and continue to deny each, any, and all allegations of wrongdoing, fault, liability, or damage whatsoever asserted by..

Also known as: Osiris Securities Settlement, Osiris Therapeutics, Inc., Settlement

Primary location: Portland United States